Imetelstat 两种剂量治疗复发或难治性骨髓纤维化的随机单盲多中心II期研究
本研究评估端粒酶抑制剂 Imetelstat 在复发或难治性骨髓纤维化患者中的疗效与安全性,随机分配至 9.4 mg/kg 或 4.7 mg/kg 静脉给药每3周一次。24周时 9.4 mg/kg 组脾脏和症状缓解率分别为 10.2% 和 32.2%,中位总生存期 29.9 个月,安全性可接受。
要点
- 9.4 mg/kg 组 24 周症状缓解率 32.2%,脾脏缓解率 10.2%。
- 9.4 mg/kg 组中位总生存期 29.9 个月。
- 常见不良事件为 3/4 级可逆性血细胞减少。
核心结论
- 在 JAKi 复发或难治性骨髓纤维化患者中,Imetelstat 9.4 mg/kg 每3周一次在症状缓解率上显示临床获益,安全性可接受。
研究设计与样本
- 随机、单盲、多中心II期研究,患者随机接受 Imetelstat 9.4 mg/kg 或 4.7 mg/kg 静脉给药每3周一次。
主要发现
- 24周时 9.4 mg/kg 组脾脏缓解率 10.2%、症状缓解率 32.2%;4.7 mg/kg 组分别为 0% 和 6.3%。
- 9.4 mg/kg 组中位总生存期 29.9 个月。
- 可评估患者中骨髓纤维化改善率 40.5%,驱动突变变异等位基因频率降低率 42.1%。
- 纤维化改善和变异等位基因频率降低与总生存期相关。
- 端粒酶活性及 hTERT 水平降低与脾脏缓解、症状缓解和总生存期相关。
临床怎么用
- 对于 JAKi 复发或难治性中危-2 或高危骨髓纤维化患者,Imetelstat 9.4 mg/kg 每3周一次可作为候选治疗选择。
局限性
- 研究提前终止入组,4.7 mg/kg 组患者允许继续接受 9.4 mg/kg 治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Patients with myelofibrosis who are relapsed or refractory (R/R) to Janus-associated kinase inhibitors (JAKis) have poor clinical outcomes including dismal overall survival (OS) that ranges between 13 and 16 months. Imetelstat, a telomerase inhibitor, was evaluated in patients with intermediate-2 or high-risk myelofibrosis R/R to JAKi in a phase II multicenter study (ClinicalTrials.gov identifier: NCT02426086). PATIENTS AND METHODS: Patients were randomly assigned to receive either imetelstat 9.4 mg/kg or 4.7 mg/kg intravenous once every 3 weeks. Spleen response (≥ 35% spleen volume reduction) and symptom response (≥ 50% reduction in total symptom score) rates at week 24 were coprimary end points. Secondary end points included OS and safety. RESULTS: Study enrollment was closed early, and patients treated with 4.7 mg/kg were permitted to continue treatment with 9.4 mg/kg. At week 24, spleen and symptom response rates were 10.2% and 32.2% in the 9.4-mg/kg arm and 0% and 6.3% in the 4.7-mg/kg arm. Treatment with imetelstat 9.4 mg/kg led to a median OS of 29.9 months and bone marrow fibrosis improvement in 40.5% and variant allele frequency reduction of driver mutations in 42.1% of evaluable patients. Fibrosis improvement and variant allele frequency reduction correlated with OS. Target inhibition was demonstrated by reduction of telomerase activity and human telomerase reverse transcriptase level and correlated with spleen response, symptom response, and OS. Most common adverse events on both arms were grade 3 or 4 reversible cytopenias. CONCLUSION: In this phase II study of two imetelstat doses, 9.4 mg/kg once every 3 weeks demonstrated clinical benefits in symptom response rate, with an acceptable safety profile for this poor-risk JAKi R/R population. Biomarker and bone marrow fibrosis assessments suggested selective effects on the malignant clone. A confirmatory phase III study is currently underway.
引用
- Mascarenhas J, Komrokji RS, Palandri F, et al. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021. PMID: 34138638. doi:10.1200/JCO.20.02864
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。